Autophagy as a therapeutic linchpin in metabolic diseases and obesity-associated...

연구 요약

Autophagy as a therapeutic linchpin in metabolic diseases and obesity-associated diabetes.

Autophagy 학술지에 발표된 이 연구는 Vakili O, Klionsky DJ, Reiter RJ 외 연구팀이 수행하였습니다.

이 연구는 'Autophagy as a therapeutic linchpin in metabolic diseases and obesity-associated diabetes.'에 대한 과학적 분석을 제공합니다.

핵심 내용

Autophagy, a conserved lysosomal degradation pathway, is increasingly recognized as a central regulator of metabolic health. Its impairment contributes directly to obesity and type 2 diabetes by disrupting nutrient sensing, stress adaptation, and organelle quality control. Hyperactivation of MTORC1 with insufficient AMPK and SIRT1 signaling suppresses autophagic flux, driving lipid accumulation, insulin resistance, and mitochondrial dysfunction. Clinically relevant consequences include adipose inflammation and hypertrophy, hepatic steatosis with impaired β-oxidation, pancreatic β-cell failure from unresolved ER stress, and skeletal muscle atrophy due to loss of proteostasis. Moreover, defective autophagy across the gut - liver - brain axis exacerbates intestinal barrier dysfunction, endotoxemia, and neuroendocrine imbalance, amplifying systemic metabolic deterioration. Emerging interventions that restore autophagic capacity, including exercise-induced AMPK activation, dietary modulation of unsaturated fatty acids, pharmacological inducers, and nanotechnology-based lysosomal re-acidification show promise in preclinical models. However, the tissue-specific duality of autophagy, where suppression may be beneficial in some contexts but harmful in others, highlights the complexity of therapeutic targeting. This review highlights current mechanistic and translational insights to position autophagy as a therapeutic linchpin in obesity-associated metabolic disease. By aligning molecular pathways with clinical outcomes, we herein highlight opportunities to develop precision strategies that harness autophagy to combat the global burden of obesity and metabolic disorders.Abbreviation: AGEs: advanced glycation endproducts; ALR: autophagic lysosomal reformation; AMPK: AMP-activated protein kinase; AT: adipose tissue; BAT: brown adipose tissue; CMA: chaperone-mediated autophagy; CR: caloric reduction/restriction; DC: diabetic cardiomyopathy; DN: diabetic nephropathy; ER: endoplasmic reticulum; ESCRT: endosomal sorting complexes required for transport; FFAs: free fatty acids; HFD: high-fat diet; HOPS: homotypic fusion and vacuole protein sorting; KO: knockout; LAMs: Lipid-associated macrophages; LD: lipid droplet; MBH: mediobasal hypothalamus; Med diet: Mediterranean diet; MDBs: Mallory-Denk bodies; MEFs: mouse embryonic fibroblasts; MTORC1: mechanistic target of rapamycin kinase complex 1; PI3K: phosphoinositide 3-kinase; PtdIns3K-CI: class III phosphatidylinositol 3-kinase complex I; T1D: type 1 diabetes; T2D: type 2 diabetes; TASCC: TOR-autophagy spatial coupling compartment; TRE: time-restricted eating; WAT: white adipose tissue.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41731726)